Hydroxychavicol Inhibits In Vitro Osteoclastogenesis via the Suppression of NF-κB Signaling Pathway

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Hydroxychavicol, a betel leaf phenolic compound, previously showed osteogenic properties.
• The impact of hydroxychavicol on osteoclast-mediated bone remodeling remains uncharacterized.

Purpose of the Study:

• To investigate the anti-osteoclastogenic effects of hydroxychavicol.
• To elucidate the underlying molecular mechanisms of hydroxychavicol's action on osteoclasts.

Main Methods:

• Hydroxychavicol's effect on receptor activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclasts derived from RAW264.7 cells and human peripheral mononuclear cells (PBMCs) was assessed.
• Key osteoclast-specific genes (cathepsin K, MMP-9, DC-STAMP) and transcription factors (NFATc1, c-Fos, c-Jun) were analyzed.
• The NF-κB signaling pathway, including p65 and Iκβα phosphorylation and p65 nuclear translocation, was investigated.

Main Results:

• Hydroxychavicol dose-dependently reduced osteoclast formation, F-actin ring development, and bone-resorbing activity.
• Expression of osteoclast-specific genes and key transcription factors (NFATc1, c-Fos, c-Jun) was significantly decreased by hydroxychavicol.
• Hydroxychavicol inhibited RANKL-induced NF-κB signaling by blocking p65 and Iκβα phosphorylation, thereby reducing p65 nuclear translocation.

Conclusions:

• Hydroxychavicol exhibits potent anti-osteoclastogenic activity in vitro.
• The mechanism involves the suppression of RANKL-induced NFATc1 expression via inhibition of the NF-κB signaling pathway.
• Hydroxychavicol demonstrates potential as a therapeutic agent for conditions involving excessive bone resorption.